Judah Frommer is ranked #2290 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Judah Frommer

Judah Frommer

Q: How accurate are Judah Frommer's stock ratings?

About 64% of Judah's ratings were profitable over a one-year hold, with an average return of +11.1% per rating, measured by 13Foresight from historical prices.

Morgan Stanley

Wall Street Analyst

★★☆☆☆

#2290

on 13Foresight · ranked by our own returns

64%

Success Rate

+11.2%

Average Return

60 of 94 calls profitable · +16.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 64% of Judah Frommer's ratings turned a profit when each position was held for 1 year — averaging +11.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

100 Buy 43 Hold 18 Sell

Judah's Stock Coverage 51 ratings · 2026-08-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
AGMB AgomAb Therapeutics NV ADR	Aug 17, 2026	BUY	Strong Buy +120.8% avg upside 6 analysts	$28.00 103.97% Upside	·	·
ZBIO Zenas BioPharma, Inc.	Aug 17, 2026	HOLD	Strong Buy +38.1% avg upside 11 analysts	$32.00 0.20% Upside	·	·
BLTE Belite Bio, Inc. ADR	Aug 17, 2026	BUY	Strong Buy +10.8% avg upside 10 analysts	$206.00 26.70% Upside	-0.4%	·
FDMT 4D Molecular Therapeutics	Aug 17, 2026	HOLD	Strong Buy +117.7% avg upside 15 analysts	—	·	·
LKFT Lakefront Biotherapeutics	Aug 17, 2026	HOLD	Buy +260.1% avg upside 24 analysts	$26.00 7.03% Downside	·	·
AVLN Avalyn Pharma Inc	Aug 13, 2026	BUY	Strong Buy +36.9% avg upside 3 analysts	$57.00 46.60% Upside	+7.3%	·
ENGN enGene Holdings	Aug 12, 2026	SELL	Buy +450.0% avg upside 13 analysts	—	-0.0%	·
BCAX Bicara Therapeutics Inc.	Aug 12, 2026	BUY	Strong Buy +24.0% avg upside 15 analysts	$37.00 48.44% Upside	+1.2%	·
KLRS Kalaris Therapeutics	Aug 12, 2026	BUY	Strong Buy +207.8% avg upside 13 analysts	$14.00 247.32% Upside	+5.8%	·
IMMX Immix Biopharma	Aug 11, 2026	BUY	Strong Buy +38.9% avg upside 9 analysts	$19.00 60.93% Upside	-3.5%	·
PROK ProKidney	Aug 11, 2026	HOLD	Buy +350.6% avg upside 12 analysts	$3.00 117.33% Upside	-17.4%	·
EVMN Evommune, Inc.	Aug 10, 2026	BUY	Strong Buy +139.5% avg upside 12 analysts	$26.00 82.89% Upside	+4.1%	·
TRVI Trevi Therapeutics	Aug 10, 2026	BUY	Strong Buy +29.8% avg upside 18 analysts	$23.00 22.12% Upside	+4.6%	·
RGNX RegenXBio	Aug 07, 2026	BUY	Strong Buy +216.4% avg upside 22 analysts	$18.00 62.58% Upside	+0.4%	·
GMAB Genmab	Aug 07, 2026	HOLD	Strong Buy +4.7% avg upside 27 analysts	$35.00 6.19% Upside	+7.3%	·
GB:0MGB Genmab A/S	Aug 07, 2026	HOLD	Strong Buy -7.0% avg upside 23 analysts	$226.12 89.37% Downside	·	·
CLDX Celldex	Aug 07, 2026	BUY	Strong Buy -1.8% avg upside 28 analysts	$46.00 10.14% Upside	+0.5%	·
ARQT Arcutis Biotherapeutics	Aug 06, 2026	BUY	Strong Buy +51.3% avg upside 14 analysts	$38.00 43.14% Upside	+0.1%	·
CMPS COMPASS Pathways	Aug 06, 2026	BUY	Strong Buy +59.0% avg upside 20 analysts	$18.00 29.47% Upside	-0.7%	·
KYMR Kymera Therapeutics	Aug 06, 2026	BUY	Strong Buy -16.0% avg upside 37 analysts	$135.00 11.17% Upside	+14.1%	·
PTCT PTC Therapeutics	Jul 31, 2026	BUY	Buy +10.3% avg upside 29 analysts	$104.00 43.12% Upside	+6.0%	·
INCY Incyte	Jul 29, 2026	HOLD	Buy -15.3% avg upside 47 analysts	$119.00 3.53% Downside	-2.8%	·
ABVX Abivax SA Sponsored ADR	Jul 24, 2026	BUY	Strong Buy +12.2% avg upside 15 analysts	$180.00 51.35% Upside	-5.6%	·
SRPT Sarepta Therapeutics	Aug 03, 2023	HOLD	Buy +208.6% avg upside 49 analysts	$139.00 671.45% Upside	+34.1%	·
EFTR eFFECTOR Therapeutics	Jun 05, 2023	BUY	Buy +16562400.0% avg upside 5 analysts	$137.50 17187400.03% Upside	·	·
IMA ImageneBio	May 16, 2023	BUY	Strong Buy +192.1% avg upside 12 analysts	$13.00 128.82% Upside	-77.3%	·
JSPR Jasper Therapeutics	May 15, 2023	BUY	Buy +3763.9% avg upside 18 analysts	$40.00 5233.37% Upside	·	·
ATAI Atai Beckley N.V.	May 12, 2023	BUY	Buy +23.4% avg upside 17 analysts	$9.00 23.36% Upside	-0.5%	·
STOK Stoke Therapeutics	May 05, 2023	BUY	Strong Buy +21.8% avg upside 18 analysts	$28.00 12.97% Downside	+0.6%	·
NAMS NewAmsterdam Pharma Company	Apr 03, 2023	BUY	Strong Buy +69.2% avg upside 19 analysts	$22.00 19.21% Downside	+63.4%	·
CADL Candel Therapeutics	Mar 31, 2023	BUY	Strong Buy +38.5% avg upside 11 analysts	$7.00 41.98% Downside	+17.0%	·
ABOS Acumen Pharmaceuticals	Mar 28, 2023	BUY	Strong Buy +174.9% avg upside 10 analysts	$13.00 374.36% Upside	+1.0%	·
FULC Fulcrum Therapeutics	Mar 09, 2023	HOLD	Hold +138.2% avg upside 14 analysts	$8.00 106.76% Upside	+129.9%	·
QURE uniQure	Feb 28, 2023	BUY	Strong Buy +21.9% avg upside 29 analysts	$55.00 16.03% Upside	-68.1%	·
INSM Insmed	Feb 24, 2023	BUY	Strong Buy +36.0% avg upside 37 analysts	$46.00 64.17% Downside	+35.9%	·
QNCX Quince Therapeutics	May 11, 2022	SELL	Buy +549.4% avg upside 16 analysts	$3.50 89.31% Downside	·	·
USFD US Foods Holding	Aug 04, 2020	BUY	Strong Buy -16.9% avg upside 23 analysts	$24.00 77.61% Downside	+51.8%	·
SFM Sprouts Farmers	Jul 30, 2020	HOLD	Buy +12.2% avg upside 28 analysts	$26.00 66.93% Downside	-7.2%	·
ACI Albertsons Companies	Jul 27, 2020	BUY	Buy +41.5% avg upside 24 analysts	$18.00 47.37% Upside	+36.3%	·
OLLI Ollie's Bargain Outlet Holding	Jul 22, 2020	HOLD	Strong Buy +24.6% avg upside 27 analysts	$95.00 24.75% Upside	-15.6%	·
COST Costco	Jul 08, 2020	HOLD	Strong Buy -9.5% avg upside 51 analysts	$328.00 65.90% Downside	+33.2%	·
KR Kroger Company	Jun 18, 2020	HOLD	Buy +8.6% avg upside 34 analysts	$35.00 37.85% Downside	+24.4%	·
FIVE Five Below	Jun 10, 2020	BUY	Strong Buy -5.7% avg upside 32 analysts	$116.00 51.28% Downside	+64.1%	·
NL:AD Koninklijke Ahold Delhaize N.V.	Jun 03, 2020	HOLD	Buy +5.1% avg upside 9 analysts	$24.00 23.88% Downside	+7.8%	·
DLTR Dollar Tree	May 28, 2020	BUY	Hold -11.0% avg upside 35 analysts	$107.00 18.03% Downside	-0.1%	·
DG Dollar General	May 22, 2020	HOLD	Buy +9.2% avg upside 32 analysts	$178.00 47.20% Upside	+15.4%	·
BJ Bj's Wholesale Club Holdings	May 21, 2020	BUY	Buy -2.0% avg upside 32 analysts	$38.00 58.95% Downside	+29.6%	·
SYY Sysco	May 05, 2020	BUY	Buy -0.9% avg upside 23 analysts	$63.00 23.16% Downside	+68.8%	·
PFGC Performance Food Group	May 04, 2020	BUY	Strong Buy +4.0% avg upside 22 analysts	$39.00 62.65% Downside	+107.7%	·
NCLH Norwegian Cruise Line	Mar 06, 2020	HOLD	Buy +30.6% avg upside 31 analysts	—	+6.5%	·
ADRNY Koninklijke Ahold Delhaize	Mar 06, 2019	HOLD	Strong Buy -21.9% avg upside 5 analysts	—	+4.9%	·

🔒 46 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Judah Frommer — Frequently Asked Questions

How accurate are Judah Frommer's stock ratings?

Based on the calls 13Foresight could measure, about 64% of Judah's ratings were profitable over a one-year hold, with an average return of +11.1% per rating, or +16.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Judah ranked on 13Foresight?

Judah Frommer is currently ranked #2290 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Judah cover?

Judah most recently has ratings on AGMB, ZBIO, BLTE, FDMT, LKFT, AVLN, ENGN, BCAX, KLRS, IMMX, PROK, EVMN and 39 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Judah Frommer

Rating Distribution

Welcome to 13Foresight!